Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity (Q45423288)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

based on heuristic

inferred from title

author name string

Xiao-su Zhao

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Chen-hua Yan

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Dai-hong Liu

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Lan-ping Xu

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Yan-rong Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Kai-yan Liu

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Ya-zhen Qin

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Yu Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Xiao-jun Huang

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

publication date

17 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

92

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1111-1119

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

CD86 is expressed on murine hematopoietic stem cells and denotes lymphopoietic potential

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Minimal residual disease diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Clinical analysis and optimization of postremission therapy for acute myeloid leukemia patients with minimal residual disease as determined by flow cytometry

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Has MRD monitoring superseded other prognostic factors in adult ALL?

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia--feasibility and safety study

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Bone-marrow transplantation (second of two parts).

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-013-1733-1

21 January 2018

Identifiers

10.1007/S00277-013-1733-1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45423288&oldid=2076925987"